October 19, 2021

Volume XI, Number 292

Advertisement
Advertisement

October 18, 2021

Subscribe to Latest Legal News and Analysis
Advertisement

Lewis Geffen of Mintz Levin looks at the Terms and Practices of East and West Coast VC Firms [VIDEO]

Lewis Geffen, Co-Chair Venture Captial & Emerging Companies Practice at Mintz Levin looks at the terms and practices of East and West Coast VC firms in the following video:

Mr. Geffen regularly represents technology-based companies, principally in the areas of biotechnology, biomedical, medtech, networking and communications, Internet, and software. His clients range in size from start-up ventures to large public companies. He routinely counsels these clients on their growth and development, advises their boards of directors and management, and assists them with a wide range of domestic and international transactions, including venture capital and other private financings, technology licensing, mergers and acquisitions, strategic alliances, and public offerings.

Lewis also regularly represents venture capital firms in both fundraising and portfolio investment activities and underwriters in public offerings and private placements of equity and debt securities.

©1994-2021 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.National Law Review, Volume V, Number 124
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Lewis Geffen, Member, Co-chair, Life Sciences Practice, Venture Capital & Emerging Companies Practice, Mintz Levin, Venture Capital Lawyer, IP Attorney, Patent Law
Member / Co-chair, Life Sciences Practice and Co-chair, Venture Capital & Emerging Companies Practice

Lewis is a corporate and licensing attorney focused on the life sciences, with decades of experience helping companies in the sector tackle strategic issues and complete complicated transactions. He is the go-to outside lawyer for preeminent biotechnology, pharmaceutical, medical device, and medtech companies, shepherding them through financing and licensing deals that fund drug development.

617.348.1834
Advertisement
Advertisement
Advertisement